Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors

Running, not enrolling · Phase 1

Conditions studied: Gastric Adenocarcinoma, Advanced Pancreatic Ductal Adenocarcinoma, Esophageal Adenocarcinoma, Biliary Tract Cancer, Other Solid Tumors

In brief

The objective of this study is to evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects with Advanced or Metastatic Solid Tumors.

Key facts

Study ID

NCT07021066

Run by

SystImmune Inc.

People needed

160

Starts

2025-07-30

Expected to finish

2027-05-31

Last updated by the study team

2026-08-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Signed the informed consent form voluntarily and agreed to follow the program requirements.
• Age ≥18 years.
• Life expectancy of ≥3 months.
• Dose Escalation and Dose Finding (Parts 1 and 2): Documented locally advanced or metastatic solid tumor(s) that are known to potentially express CLDN18.2, as defined below, that have recurred or progressed on at least 1 line of prior systemic therapy (refer to Section 6.3.1), have no other standard of care options, and have no available curative options, including the following:
• Gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (AC): Participants with CLDN18.2, HER2, PD-L1, and/or microsatellite instability high (MSI-H)/mismatch repair deficiency (dMMR) positive tumors must have received targeted treatment in their prior lines of therapy.
• Pancreatic ductal AC (PDAC): Participants who have received at least 1 line of standard therapy.
• Esophageal AC (EAC): Participants with HER2, PD-L1, and/or MSI-H/dMMR positive tumors must have received targeted treatment in their prior lines of therapy.
• Biliary tract cancers (BTCs): Participants with HER2 overexpression, NTRK fusions, KRAS mutations, IDH1 mutations, FGFR2 fusions, BRAF mutations, and/or MSI-H/ dMMR positive tumors must have received targeted treatment in their prior lines of therapy.
• Other solid tumors not specified above may be included if they have documented CLDN18.2 expression by IHC (1+). As applicable per standard of care, participants with HER2 and/or PD-L1 positive tumors must have received targeted treatment in their prior lines of therapy, and participants with MSI-H or dMMR positive tumors must have received immune checkpoint inhibitor.
• Agree to provide most recent existing tumor samples (formalin-fixed paraffin-embedded [FFPE] tissue block or slides) from primary or metastatic sites (see details in Section 7.1.1) for tissue-based evaluation of CLDN18.2 expression. A fresh biopsy is required if no archival/FFPE block or slides are available. Re-biopsy is recommended if the participant previously received a CLDN18.2-directed treatment.
• At least 1 measurable lesion based on RECIST v1.1.
• Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 1.
• Toxicity of previous antitumor therapy has returned to Grade ≤1 as defined by the National Cancer Institute (NCI) CTCAE v5.0.
• Exceptions: Alopecia and endocrinopathies controlled by replacement therapy must be Grade ≤2.
• No serious cardiac dysfunction, left ventricular ejection fraction ≥50%.
• Adequate organ function before enrollment, defined as follows:
• Marrow function: absolute neutrophil count (ANC) ≥1.5×109/L, platelet (PLT) count ≥100×109/L, hemoglobin (Hb) ≥9.0 g/dL (blood transfusion, platelet transfusion, erythropoietin (EPO), hematopoiesis agents, and G-CSF use are not allowed 1 week prior to screening).
• Hepatic function: total bilirubin (TBIL) ≤1.5 × upper limit of normal (ULN) (≤3 × ULN for participants with Gilbert's syndrome or liver metastasis at baseline); aspartate aminotransferase (AST) and alanine aminotransferase (ALT) without liver metastasis ≤3.0 × ULN; AST and ALT with liver metastasis ≤5.0 × ULN.
• Note: For participants with Gilbert's syndrome, conjugated bilirubin ≤1.5 × ULN and TBIL <3.0 × ULN in the absence of liver metastases.
• Renal function: creatinine clearance (CrCl) ≥60 mL/min (Cockcroft-Gault equation) or estimated glomerular filtration rate (eGFR) ≥50 mL/min/1.73 m2 (Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] creatinine equation).
• Coagulation parameters: International normalized ratio (INR) ≤1.5 × ULN, and activated partial thromboplastin time (aPTT) ≤1.5 × ULN, unless receiving anticoagulation therapy with prothrombin time and aPTT levels within the intended therapeutic range.
• Sexually active fertile participants and their partners must agree to use highly effective methods of contraception (defined in Section 17.5 [Appendix E]) during the course of the study and after the last dose of study treatment (7 months for women and 4 months for men). An additional contraceptive method, such as a barrier method (eg, condom), is recommended.
• Individuals of childbearing potential (IOCBP) must have a negative serum pregnancy test at screening and must be nonlactating. Female participants are considered IOCBP unless one of the following criteria are met: documented permanent sterilization (hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) or documented postmenopausal status (defined as 12 months of amenorrhea in a woman >45 years old in the absence of other biological or physiological causes). In addition, females <55 years old must have a serum follicle-stimulating hormone (FSH) level >40 mIU/mL to confirm menopause.
• Note: Documentation may include review of medical records, medical examination, or medical history interview by study site staff.
• All participants must be willing to receive prophylactic G-CSF during their time on study (see Section 6.3.4.5).

You may not qualify if…

• Chemotherapy, biological therapy, immunotherapy, radical radiotherapy, targeted therapy (including small-molecule inhibitor of tyrosine kinase), or other antitumor therapy within 4 weeks or 5 half-lives (whichever is shorter) prior to the first administration of study drug; major surgery within 4 weeks prior to the first administration; mitomycin and nitrosoureas treatment within 6 weeks prior to the first administration.
• Participants with history of severe heart disease such as symptomatic congestive heart failure (CHF) Grade ≥2 (CTCAE v5.0), New York Heart Association (NYHA) Grade ≥2 heart failure at any time, or history of myocardial infarction or unstable angina pectoris within 6 months before enrollment.
• Participants with prolonged QT interval corrected (QTcF) >470 msec, complete left bundle branch block, Grade 3 atrioventricular block.
• Active autoimmune diseases and inflammatory diseases such as systemic lupus erythematosus, psoriasis requiring systemic treatment, rheumatoid arthritis, inflammatory bowel disease, or Hashimoto's thyroiditis..
• Exception: Participants with skin diseases that do not require systemic treatment (such as vitiligo, psoriasis); well-controlled type 1 diabetes; or hypothyroidism are permitted.
• Note: For autoimmune conditions that are active but stable, low grade, and on systemic therapy, discussion with the medical monitor is required prior to screening.
• Participants with other prior malignancies.
• Exceptions: Basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and/or carcinoma in situ after adequate resection, or other malignancy treated with curative intent with a disease-free interval of at least 3 years prior to screening.
• Participants with advanced or clinically significant lung diseases such as poorly controlled chronic obstructive pulmonary disease (COPD) or asthma, restrictive lung disease, or pulmonary hypertension.
• Participants who have a history of noninfectious interstitial lung disease (ILD)/pneumonitis that required treatment with steroids or have current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening.
• Participants with stroke or transient ischemic attack (TIA) within 6 months before enrollment.
• Participants with a thromboembolic event (eg, deep vein thrombosis, pulmonary embolism) within 6 months before enrollment.
• Exception: Those who are clinically stable and receiving treatment with adequate anticoagulant therapy for at least 3 weeks before enrollment may participate.
• Participants with primary tumors in the central nervous system (CNS), or active or untreated CNS metastases and/or carcinomatous meningitis.
• Exception: Participants with previously treated brain metastases may participate provided they are clinically stable for at least 4 weeks, have no evidence of new or enlarging brain metastases, and have no requirements for corticosteroids 14 days prior to dosing with the IP. Participants on low-dose corticosteroids (<10 mg prednisone or equivalent/day) may participate.
• Participants with pre-existing Grade ≥2 peripheral neuropathy.
• Participants who have a history of anaphylaxis or severe hypersensitivity to recombinant humanized antibodies, human-mouse chimeric antibodies, or any of the components of BL-M05D1.
• Participants who are receiving treatment with systemic glucocorticoids >10 mg/day equivalent of prednisone.
• Exceptions:
• Treatment of COPD and infusion-related reactions (IRRs) is permitted.
• Treatment with low-dose glucocorticoids (≤10 mg/day equivalent of prednisone), including antiemetics, is permitted.
• The chronic use of topical, inhaled, and locally injected steroids is permitted.
• Participants with known or suspected human immunodeficiency virus (HIV) infection (HIV antibody positive).
• Exceptions: Participants are allowed to participate if all the following criteria are met:
• undetectable HIV RNA and CD4 count ≥350 cells/μL at screening;

Where it is running

• HonorHealth — Scottsdale, Arizona, United States
• Valkyrie Clinical Trials — Los Angeles, California, United States
• University of Colorado Health — Aurora, Colorado, United States
• Yale Cancer Center — New Haven, Connecticut, United States
• Ochsner Medical Center — New Orleans, Louisiana, United States
• University of Michigan — Ann Arbor, Michigan, United States
• Hackensack University Medical Center — Hackensack, New Jersey, United States
• Sarah Cannon Research Institute - Oncology Partners — Nashville, Tennessee, United States
• NEXT Oncology- Austin — Austin, Texas, United States
• NEXT Oncology- Dallas — Dallas, Texas, United States
• NEXT Oncology San Antonio — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.